Chemicals
Showing 12301–12450 of 41137 results
-
BTC is a low affinity calcium indicator (Kd = 7-26 µM) that displays excitation/emission spectra of 401/529 nm, respectively. It exhibits a shift in the excitation maximum from approximately 480 to 401 nm upon calcium binding, enabling determination of ratiometric calcium measurements.{22804} BTC is suitable for detecting elevated calcium levels associated with activation of smooth muscle, neurons, and intracellular calcium stores.{22804,31960}
Brand:CaymanSKU:20423 -Available on backorder
BTC AM is a cell-permeable acetoxy-methyl ester of BTC (Item No. 20423). As BTC AM enters cells, it is hydrolyzed by intracellular esterases to produce BTC. BTC is a low affinity calcium indicator (Kd = 7-26 µM) that displays excitation/emission spectra of 401/529 nm, respectively. It exhibits a shift in the excitation maximum from approximately 480 to 401 nm upon calcium binding, enabling determination of ratiometric calcium measurements.{22804} BTC is suitable for detecting elevated calcium levels associated with activation of smooth muscle, neurons, and intracellular calcium stores.{22804,31960}
Brand:CaymanSKU:20424 -Available on backorder
BTS is an inhibitor of skeletal muscle myosin II ATPase activity that reduces the affinity of ADP-myosin for actin.{54102} It inhibits calcium-stimulated ATPase activity of rabbit muscle myosin subfragment 1 (S1) in an actin-independent manner with an IC50 value of approximately 5 µM. It is selective for calcium-stimulated myosin II over human platelet myosin II, kinesin, pyruvate kinase, and lactate dehydrogenase at 100 µM. BTS (2 µM) inhibits the activity of skeletal muscle myosin, reversibly reducing the sliding velocity of heavy meromyosin in a gliding-filament assay. It inhibits isometric calcium-activated tension in isolated fast-twitch rabbit psoas muscle fibers (IC50 = ~3 µM) but not in isolated slow-twitch rat trabeculae and papillary cardiac muscle. BTS is also an intermediate in the synthesis of sulfonamides.{54103}
Brand:CaymanSKU:30099 - 1 gAvailable on backorder
BTS is an inhibitor of skeletal muscle myosin II ATPase activity that reduces the affinity of ADP-myosin for actin.{54102} It inhibits calcium-stimulated ATPase activity of rabbit muscle myosin subfragment 1 (S1) in an actin-independent manner with an IC50 value of approximately 5 µM. It is selective for calcium-stimulated myosin II over human platelet myosin II, kinesin, pyruvate kinase, and lactate dehydrogenase at 100 µM. BTS (2 µM) inhibits the activity of skeletal muscle myosin, reversibly reducing the sliding velocity of heavy meromyosin in a gliding-filament assay. It inhibits isometric calcium-activated tension in isolated fast-twitch rabbit psoas muscle fibers (IC50 = ~3 µM) but not in isolated slow-twitch rat trabeculae and papillary cardiac muscle. BTS is also an intermediate in the synthesis of sulfonamides.{54103}
Brand:CaymanSKU:30099 - 10 gAvailable on backorder
BTS is an inhibitor of skeletal muscle myosin II ATPase activity that reduces the affinity of ADP-myosin for actin.{54102} It inhibits calcium-stimulated ATPase activity of rabbit muscle myosin subfragment 1 (S1) in an actin-independent manner with an IC50 value of approximately 5 µM. It is selective for calcium-stimulated myosin II over human platelet myosin II, kinesin, pyruvate kinase, and lactate dehydrogenase at 100 µM. BTS (2 µM) inhibits the activity of skeletal muscle myosin, reversibly reducing the sliding velocity of heavy meromyosin in a gliding-filament assay. It inhibits isometric calcium-activated tension in isolated fast-twitch rabbit psoas muscle fibers (IC50 = ~3 µM) but not in isolated slow-twitch rat trabeculae and papillary cardiac muscle. BTS is also an intermediate in the synthesis of sulfonamides.{54103}
Brand:CaymanSKU:30099 - 25 gAvailable on backorder
BTS is an inhibitor of skeletal muscle myosin II ATPase activity that reduces the affinity of ADP-myosin for actin.{54102} It inhibits calcium-stimulated ATPase activity of rabbit muscle myosin subfragment 1 (S1) in an actin-independent manner with an IC50 value of approximately 5 µM. It is selective for calcium-stimulated myosin II over human platelet myosin II, kinesin, pyruvate kinase, and lactate dehydrogenase at 100 µM. BTS (2 µM) inhibits the activity of skeletal muscle myosin, reversibly reducing the sliding velocity of heavy meromyosin in a gliding-filament assay. It inhibits isometric calcium-activated tension in isolated fast-twitch rabbit psoas muscle fibers (IC50 = ~3 µM) but not in isolated slow-twitch rat trabeculae and papillary cardiac muscle. BTS is also an intermediate in the synthesis of sulfonamides.{54103}
Brand:CaymanSKU:30099 - 5 gAvailable on backorder
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).{43310} It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Brand:CaymanSKU:25623 - 1 mgAvailable on backorder
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).{43310} It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Brand:CaymanSKU:25623 - 10 mgAvailable on backorder
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).{43310} It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Brand:CaymanSKU:25623 - 25 mgAvailable on backorder
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).{43310} It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Brand:CaymanSKU:25623 - 5 mgAvailable on backorder
BTZ043 is an antibiotic with antimycobacterial activity.{41991} It targets mycobacterial cell wall synthesis by inhibiting DprE1, which, in conjunction with DprE2, catalyzes the epimerization of decaprenylphosphoryl ribose to decaprenylphosphoryl arabinose. BTZ043 is active against various Mycobacterium species in vitro, including M. smegmatis, M. bovis, and M. tuberculosis (MICs = 4, 2, and 1 ng/ml, respectively), as well as the actinobacterium N. brasiliensis (MIC50 = 0.125 μg/ml).{41991,41992} It is also active against M. tuberculosis in RAW 264.7 murine macrophages (MIC = M. tuberculosis cells in lung and spleen in a mouse model of chronic tuberculosis infection.
Brand:CaymanSKU:22930 - 1 mgAvailable on backorder
BTZ043 is an antibiotic with antimycobacterial activity.{41991} It targets mycobacterial cell wall synthesis by inhibiting DprE1, which, in conjunction with DprE2, catalyzes the epimerization of decaprenylphosphoryl ribose to decaprenylphosphoryl arabinose. BTZ043 is active against various Mycobacterium species in vitro, including M. smegmatis, M. bovis, and M. tuberculosis (MICs = 4, 2, and 1 ng/ml, respectively), as well as the actinobacterium N. brasiliensis (MIC50 = 0.125 μg/ml).{41991,41992} It is also active against M. tuberculosis in RAW 264.7 murine macrophages (MIC = M. tuberculosis cells in lung and spleen in a mouse model of chronic tuberculosis infection.
Brand:CaymanSKU:22930 - 10 mgAvailable on backorder
BTZ043 is an antibiotic with antimycobacterial activity.{41991} It targets mycobacterial cell wall synthesis by inhibiting DprE1, which, in conjunction with DprE2, catalyzes the epimerization of decaprenylphosphoryl ribose to decaprenylphosphoryl arabinose. BTZ043 is active against various Mycobacterium species in vitro, including M. smegmatis, M. bovis, and M. tuberculosis (MICs = 4, 2, and 1 ng/ml, respectively), as well as the actinobacterium N. brasiliensis (MIC50 = 0.125 μg/ml).{41991,41992} It is also active against M. tuberculosis in RAW 264.7 murine macrophages (MIC = M. tuberculosis cells in lung and spleen in a mouse model of chronic tuberculosis infection.
Brand:CaymanSKU:22930 - 25 mgAvailable on backorder
BTZ043 is an antibiotic with antimycobacterial activity.{41991} It targets mycobacterial cell wall synthesis by inhibiting DprE1, which, in conjunction with DprE2, catalyzes the epimerization of decaprenylphosphoryl ribose to decaprenylphosphoryl arabinose. BTZ043 is active against various Mycobacterium species in vitro, including M. smegmatis, M. bovis, and M. tuberculosis (MICs = 4, 2, and 1 ng/ml, respectively), as well as the actinobacterium N. brasiliensis (MIC50 = 0.125 μg/ml).{41991,41992} It is also active against M. tuberculosis in RAW 264.7 murine macrophages (MIC = M. tuberculosis cells in lung and spleen in a mouse model of chronic tuberculosis infection.
Brand:CaymanSKU:22930 - 5 mgAvailable on backorder
BTZO-1 is an antioxidant response element (ARE) activator with cardioprotective activity.{45205} It increases expression of an ARE-luciferase reporter construct in H9c2 cells in a concentration-dependent manner as well as mRNA expression of the ARE-regulated genes for the glutathione S-transferase Ya subunit (GST Ya) and heme oxygenase-1 (HO-1) in neonatal rat cardiomyocytes. BTZO-1 binds to macrophage migration inhibitory factor (MIF; Kd = 68.6 nM) and increases expression of GST Ya in H9c2 cells in a MIF-dependent manner when used at a concentration of 3 μM. It inhibits cell death induced by serum deprivation or doxorubicin (Item No. 15007) in neonatal rat cardiomyocytes in a concentration-dependent manner.
Brand:CaymanSKU:28161 - 10 mgAvailable on backorder
BTZO-1 is an antioxidant response element (ARE) activator with cardioprotective activity.{45205} It increases expression of an ARE-luciferase reporter construct in H9c2 cells in a concentration-dependent manner as well as mRNA expression of the ARE-regulated genes for the glutathione S-transferase Ya subunit (GST Ya) and heme oxygenase-1 (HO-1) in neonatal rat cardiomyocytes. BTZO-1 binds to macrophage migration inhibitory factor (MIF; Kd = 68.6 nM) and increases expression of GST Ya in H9c2 cells in a MIF-dependent manner when used at a concentration of 3 μM. It inhibits cell death induced by serum deprivation or doxorubicin (Item No. 15007) in neonatal rat cardiomyocytes in a concentration-dependent manner.
Brand:CaymanSKU:28161 - 25 mgAvailable on backorder
BTZO-1 is an antioxidant response element (ARE) activator with cardioprotective activity.{45205} It increases expression of an ARE-luciferase reporter construct in H9c2 cells in a concentration-dependent manner as well as mRNA expression of the ARE-regulated genes for the glutathione S-transferase Ya subunit (GST Ya) and heme oxygenase-1 (HO-1) in neonatal rat cardiomyocytes. BTZO-1 binds to macrophage migration inhibitory factor (MIF; Kd = 68.6 nM) and increases expression of GST Ya in H9c2 cells in a MIF-dependent manner when used at a concentration of 3 μM. It inhibits cell death induced by serum deprivation or doxorubicin (Item No. 15007) in neonatal rat cardiomyocytes in a concentration-dependent manner.
Brand:CaymanSKU:28161 - 5 mgAvailable on backorder
Bucindolol is a third-generation, non-selective β-adrenergic receptor blocker that acts on both β1 and β2 receptors.{33520,33521} Formulations containing β-blockers, such as bucindolol, are used in managing chronic heart failure.{33522} Bucindolol is also a weak α1-adrenoceptor antagonist, which may be linked to a mild vasodilator benefit.{33520,33522}
Brand:CaymanSKU:21070 -Out of stock
Bucindolol is a third-generation, non-selective β-adrenergic receptor blocker that acts on both β1 and β2 receptors.{33520,33521} Formulations containing β-blockers, such as bucindolol, are used in managing chronic heart failure.{33522} Bucindolol is also a weak α1-adrenoceptor antagonist, which may be linked to a mild vasodilator benefit.{33520,33522}
Brand:CaymanSKU:21070 -Out of stock
Bucindolol is a third-generation, non-selective β-adrenergic receptor blocker that acts on both β1 and β2 receptors.{33520,33521} Formulations containing β-blockers, such as bucindolol, are used in managing chronic heart failure.{33522} Bucindolol is also a weak α1-adrenoceptor antagonist, which may be linked to a mild vasodilator benefit.{33520,33522}
Brand:CaymanSKU:21070 -Out of stock
Bucladesine is a cell-permeable, cyclic nucleotide derivative that mimics the action of endogenous cyclic adenosine monophosphate (cAMP) and is a phosphodiesterase inhibitor.{23143,23142} Because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions, bucladesine is widely used in a variety of research applications.
Brand:CaymanSKU:- Bucladesine is a cell-permeable, cyclic nucleotide derivative that mimics the action of endogenous cyclic adenosine monophosphate (cAMP) and is a phosphodiesterase inhibitor.{23143,23142} Because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions, bucladesine is widely used in a variety of research applications.
Brand:CaymanSKU:- Bucladesine is a cell-permeable, cyclic nucleotide derivative that mimics the action of endogenous cyclic adenosine monophosphate (cAMP) and is a phosphodiesterase inhibitor.{23143,23142} Because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions, bucladesine is widely used in a variety of research applications.
Brand:CaymanSKU:- Bucladesine is a cell-permeable, cyclic nucleotide derivative that mimics the action of endogenous cyclic adenosine monophosphate (cAMP) and is a phosphodiesterase inhibitor.{23143,23142} Because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions, bucladesine is widely used in a variety of research applications.
Brand:CaymanSKU:-
Buclizine is an antihistamine.{36933} It reduces bronchoconstriction and lethality induced by aerosolized histamine in guinea pigs when administered at a dose of 1 mg/kg. Buclizine (40-200 mg/kg) induces gross malformations, including fusion of the tongue to the palate, cleft palate, micrognathia, and micromelia, and bone malformations in rats.{36934} It also inhibits cancer cell growth by binding to translationally controlled tumor protein (TCTP) and inducing cell differentiation.{36935} Formulations containing buclizine have been used to treat nausea induced by pregnancy and motion sickness.
Brand:CaymanSKU:25641 - 1 gAvailable on backorder
Buclizine is an antihistamine.{36933} It reduces bronchoconstriction and lethality induced by aerosolized histamine in guinea pigs when administered at a dose of 1 mg/kg. Buclizine (40-200 mg/kg) induces gross malformations, including fusion of the tongue to the palate, cleft palate, micrognathia, and micromelia, and bone malformations in rats.{36934} It also inhibits cancer cell growth by binding to translationally controlled tumor protein (TCTP) and inducing cell differentiation.{36935} Formulations containing buclizine have been used to treat nausea induced by pregnancy and motion sickness.
Brand:CaymanSKU:25641 - 100 mgAvailable on backorder
Buclizine is an antihistamine.{36933} It reduces bronchoconstriction and lethality induced by aerosolized histamine in guinea pigs when administered at a dose of 1 mg/kg. Buclizine (40-200 mg/kg) induces gross malformations, including fusion of the tongue to the palate, cleft palate, micrognathia, and micromelia, and bone malformations in rats.{36934} It also inhibits cancer cell growth by binding to translationally controlled tumor protein (TCTP) and inducing cell differentiation.{36935} Formulations containing buclizine have been used to treat nausea induced by pregnancy and motion sickness.
Brand:CaymanSKU:25641 - 50 mgAvailable on backorder
Buclizine is an antihistamine.{36933} It reduces bronchoconstriction and lethality induced by aerosolized histamine in guinea pigs when administered at a dose of 1 mg/kg. Buclizine (40-200 mg/kg) induces gross malformations, including fusion of the tongue to the palate, cleft palate, micrognathia, and micromelia, and bone malformations in rats.{36934} It also inhibits cancer cell growth by binding to translationally controlled tumor protein (TCTP) and inducing cell differentiation.{36935} Formulations containing buclizine have been used to treat nausea induced by pregnancy and motion sickness.
Brand:CaymanSKU:25641 - 500 mgAvailable on backorder
Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay).{41565} It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM).{25238} It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg.{24240} Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis.{52378} Formulations containing budesonide have been used in the treatment of Crohn’s disease, ulcerative colitis, allergic rhinitis, and asthma.
Brand:CaymanSKU:- Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay).{41565} It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM).{25238} It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg.{24240} Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis.{52378} Formulations containing budesonide have been used in the treatment of Crohn’s disease, ulcerative colitis, allergic rhinitis, and asthma.
Brand:CaymanSKU:- Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay).{41565} It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM).{25238} It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg.{24240} Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis.{52378} Formulations containing budesonide have been used in the treatment of Crohn’s disease, ulcerative colitis, allergic rhinitis, and asthma.
Brand:CaymanSKU:- Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay).{41565} It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM).{25238} It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg.{24240} Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis.{52378} Formulations containing budesonide have been used in the treatment of Crohn’s disease, ulcerative colitis, allergic rhinitis, and asthma.
Brand:CaymanSKU:-
Budesonide-d8 is intended for use as an internal standard for the quantification of budesonide (Item No. 15407) by GC- or LC-MS. Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay).{41565} It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM).{25238} It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg.{24240} Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis.{52378} Formulations containing budesonide have been used in the treatment of Crohn’s disease, ulcerative colitis, allergic rhinitis, and asthma.
Brand:CaymanSKU:30046 - 1 mgAvailable on backorder
Bufalin is a cardiotonic steroid first isolated from toad venom and used in traditional Asian medicine.{29917,29914} It inhibits the Na+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the α1, α2, and α3 subunits, respectively).{29469} Intravenously administered bufalin is cleared rapidly, with a plasma half-life of 25 minutes in dogs and rats.{29913} Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.{25457} It can also impact the action and expression of several other proteins and kinases as well as induce apoptosis in various cancer cells.{29915,29916}
Brand:CaymanSKU:- Bufalin is a cardiotonic steroid first isolated from toad venom and used in traditional Asian medicine.{29917,29914} It inhibits the Na+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the α1, α2, and α3 subunits, respectively).{29469} Intravenously administered bufalin is cleared rapidly, with a plasma half-life of 25 minutes in dogs and rats.{29913} Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.{25457} It can also impact the action and expression of several other proteins and kinases as well as induce apoptosis in various cancer cells.{29915,29916}
Brand:CaymanSKU:- Bufalin is a cardiotonic steroid first isolated from toad venom and used in traditional Asian medicine.{29917,29914} It inhibits the Na+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the α1, α2, and α3 subunits, respectively).{29469} Intravenously administered bufalin is cleared rapidly, with a plasma half-life of 25 minutes in dogs and rats.{29913} Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.{25457} It can also impact the action and expression of several other proteins and kinases as well as induce apoptosis in various cancer cells.{29915,29916}
Brand:CaymanSKU:- Bufalin is a cardiotonic steroid first isolated from toad venom and used in traditional Asian medicine.{29917,29914} It inhibits the Na+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the α1, α2, and α3 subunits, respectively).{29469} Intravenously administered bufalin is cleared rapidly, with a plasma half-life of 25 minutes in dogs and rats.{29913} Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.{25457} It can also impact the action and expression of several other proteins and kinases as well as induce apoptosis in various cancer cells.{29915,29916}
Brand:CaymanSKU:-
Bufexamac is an NSAID and inhibitor of the class IIb histone deacetylases HDAC6 and HDAC10.{43497} It inhibits the production of IFN-α in peripheral blood mononuclear cells (PBMCs; EC50 = 8.9 µM). Bufexamac induces hyperacetylation of tubulin (IC50 = 2.9 µM), a major substrate of HDAC6, without increasing acetylation of the class I HDAC substrates H3K5 or H3K9/K14. It also inhibits leukotriene A4 (LTA4) hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively) and 5-lipoxygenase (5-LO) activity (IC50 = 27 µM).{43498,43499} Bufexamac inhibits the production of leukotriene B4 (LTB4; Item No. 20110) in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration when used at concentrations of 50 and 100 µM.{43498} It also reduces neutrophil levels, as well as protein levels of TNF-α and IL-1β, in bronchoalveolar lavage fluid (BALF) in a mouse model of LPS-induced acute lung injury when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:26068 - 100 mgAvailable on backorder
Bufexamac is an NSAID and inhibitor of the class IIb histone deacetylases HDAC6 and HDAC10.{43497} It inhibits the production of IFN-α in peripheral blood mononuclear cells (PBMCs; EC50 = 8.9 µM). Bufexamac induces hyperacetylation of tubulin (IC50 = 2.9 µM), a major substrate of HDAC6, without increasing acetylation of the class I HDAC substrates H3K5 or H3K9/K14. It also inhibits leukotriene A4 (LTA4) hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively) and 5-lipoxygenase (5-LO) activity (IC50 = 27 µM).{43498,43499} Bufexamac inhibits the production of leukotriene B4 (LTB4; Item No. 20110) in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration when used at concentrations of 50 and 100 µM.{43498} It also reduces neutrophil levels, as well as protein levels of TNF-α and IL-1β, in bronchoalveolar lavage fluid (BALF) in a mouse model of LPS-induced acute lung injury when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:26068 - 25 mgAvailable on backorder
Bufexamac is an NSAID and inhibitor of the class IIb histone deacetylases HDAC6 and HDAC10.{43497} It inhibits the production of IFN-α in peripheral blood mononuclear cells (PBMCs; EC50 = 8.9 µM). Bufexamac induces hyperacetylation of tubulin (IC50 = 2.9 µM), a major substrate of HDAC6, without increasing acetylation of the class I HDAC substrates H3K5 or H3K9/K14. It also inhibits leukotriene A4 (LTA4) hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively) and 5-lipoxygenase (5-LO) activity (IC50 = 27 µM).{43498,43499} Bufexamac inhibits the production of leukotriene B4 (LTB4; Item No. 20110) in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration when used at concentrations of 50 and 100 µM.{43498} It also reduces neutrophil levels, as well as protein levels of TNF-α and IL-1β, in bronchoalveolar lavage fluid (BALF) in a mouse model of LPS-induced acute lung injury when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:26068 - 250 mgAvailable on backorder
Bufexamac is an NSAID and inhibitor of the class IIb histone deacetylases HDAC6 and HDAC10.{43497} It inhibits the production of IFN-α in peripheral blood mononuclear cells (PBMCs; EC50 = 8.9 µM). Bufexamac induces hyperacetylation of tubulin (IC50 = 2.9 µM), a major substrate of HDAC6, without increasing acetylation of the class I HDAC substrates H3K5 or H3K9/K14. It also inhibits leukotriene A4 (LTA4) hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively) and 5-lipoxygenase (5-LO) activity (IC50 = 27 µM).{43498,43499} Bufexamac inhibits the production of leukotriene B4 (LTB4; Item No. 20110) in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration when used at concentrations of 50 and 100 µM.{43498} It also reduces neutrophil levels, as well as protein levels of TNF-α and IL-1β, in bronchoalveolar lavage fluid (BALF) in a mouse model of LPS-induced acute lung injury when administered at a dose of 100 mg/kg.
Brand:CaymanSKU:26068 - 50 mgAvailable on backorder
Buflomedil is a non-selective antagonist of α-adrenergic receptors (α-ARs) and vasoactive compound.{58021,58022,58023,58024} It binds to rat α1A- and α1B-ARs (Kis = 4.06 and 6.84 µM, respectively) and human platelet α2-ARs (IC50 = 1 µM) in radioligand binding assays.{58021,58022} Buflomedil (0.06-60 µM) inhibits contraction of isolated canine saphenous veins induced by phenylephrine, clonidine (Item No. 15949), sympathetic nerve stimulation, or norepinephrine.{58023} It inhibits ADP-, collagen-, or epinephrine-induced aggregation of isolated human platelets when used at a concentration of 100 µM.{58022} Buflomedil (10 mg/kg) reduces hippocampal neuronal cell death in a rat model of carotid clamping-induced ischemia-reperfusion injury.{58024}
Brand:CaymanSKU:31184 - 10 gAvailable on backorder
Buflomedil is a non-selective antagonist of α-adrenergic receptors (α-ARs) and vasoactive compound.{58021,58022,58023,58024} It binds to rat α1A- and α1B-ARs (Kis = 4.06 and 6.84 µM, respectively) and human platelet α2-ARs (IC50 = 1 µM) in radioligand binding assays.{58021,58022} Buflomedil (0.06-60 µM) inhibits contraction of isolated canine saphenous veins induced by phenylephrine, clonidine (Item No. 15949), sympathetic nerve stimulation, or norepinephrine.{58023} It inhibits ADP-, collagen-, or epinephrine-induced aggregation of isolated human platelets when used at a concentration of 100 µM.{58022} Buflomedil (10 mg/kg) reduces hippocampal neuronal cell death in a rat model of carotid clamping-induced ischemia-reperfusion injury.{58024}
Brand:CaymanSKU:31184 - 5 gAvailable on backorder
Buformin is a biguanide derivative with antihyperglycemic activity. It delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose utilization in peripheral cells, and inhibits hepatic gluconeogenesis.{29950} It can also deactivate the glycolytic pathway by suppressing glyceraldehyde 3-phosphate dehydrogenase gene expression, which can lead to lactic acidosis.{29952} Biguanides, such as buformin, are reported to inhibit the mitochondrial respiratory complex I by inhibiting ubiquinone reduction and by stimulating reactive oxygen species production via the complex I flavin.{29949} Some biguanides, including buformin, can also inhibit the mitochondrial ATP synthase.{29949} Buformin has also been examined for antitumor activity due to its ability to disrupt the unfolded protein response transcription program during glucose deprivation, which induces cell death in glucose-deprived tumor cells.{29951}
Brand:CaymanSKU:-Available on backorder
Buformin is a biguanide derivative with antihyperglycemic activity. It delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose utilization in peripheral cells, and inhibits hepatic gluconeogenesis.{29950} It can also deactivate the glycolytic pathway by suppressing glyceraldehyde 3-phosphate dehydrogenase gene expression, which can lead to lactic acidosis.{29952} Biguanides, such as buformin, are reported to inhibit the mitochondrial respiratory complex I by inhibiting ubiquinone reduction and by stimulating reactive oxygen species production via the complex I flavin.{29949} Some biguanides, including buformin, can also inhibit the mitochondrial ATP synthase.{29949} Buformin has also been examined for antitumor activity due to its ability to disrupt the unfolded protein response transcription program during glucose deprivation, which induces cell death in glucose-deprived tumor cells.{29951}
Brand:CaymanSKU:-Available on backorder
Buformin is a biguanide derivative with antihyperglycemic activity. It delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose utilization in peripheral cells, and inhibits hepatic gluconeogenesis.{29950} It can also deactivate the glycolytic pathway by suppressing glyceraldehyde 3-phosphate dehydrogenase gene expression, which can lead to lactic acidosis.{29952} Biguanides, such as buformin, are reported to inhibit the mitochondrial respiratory complex I by inhibiting ubiquinone reduction and by stimulating reactive oxygen species production via the complex I flavin.{29949} Some biguanides, including buformin, can also inhibit the mitochondrial ATP synthase.{29949} Buformin has also been examined for antitumor activity due to its ability to disrupt the unfolded protein response transcription program during glucose deprivation, which induces cell death in glucose-deprived tumor cells.{29951}
Brand:CaymanSKU:-Available on backorder
Bufuralol is a non-specific β-adrenergic blocker with affinity for both β1 and β2-adrenergic receptors. It acts as a potent β-adrenoceptor antagonist with partial agonist activity.{29043} It is primarily metabolized by cytochrome P450 (CYP) isoform CYP2D6, with CYP1A2 and CYP2C19 also contributing to 1’-hydroxylation.{29042}
Brand:CaymanSKU:-Available on backorder
Bufuralol is a non-specific β-adrenergic blocker with affinity for both β1 and β2-adrenergic receptors. It acts as a potent β-adrenoceptor antagonist with partial agonist activity.{29043} It is primarily metabolized by cytochrome P450 (CYP) isoform CYP2D6, with CYP1A2 and CYP2C19 also contributing to 1’-hydroxylation.{29042}
Brand:CaymanSKU:-Available on backorder
Bufuralol is a non-specific β-adrenergic blocker with affinity for both β1 and β2-adrenergic receptors. It acts as a potent β-adrenoceptor antagonist with partial agonist activity.{29043} It is primarily metabolized by cytochrome P450 (CYP) isoform CYP2D6, with CYP1A2 and CYP2C19 also contributing to 1’-hydroxylation.{29042}
Brand:CaymanSKU:-Available on backorder
Bufuralol-d9 is intended for use as an internal standard for the quantification of bufuralol (Item No. 17794) by GC- or LC-MS. Bufuralol is a non-selective antagonist of β-adrenergic receptors (β-ARs) that also has partial agonist activity.{29042,29043,45566} It decreases mean arterial blood pressure and increases abdominal aortic blood flow in anesthetized cats when administered intravenously at doses of 0.3 and 1 mg/kg.{45566} Bufuralol is hydroxylated at the 1′ position by the cytochrome P450 (CYP) isoform CYP2D6 and has been used as a substrate to measure CYP2D6 activity.{37036,29042,11736,45565}
Brand:CaymanSKU:29081 - 1 mgAvailable on backorder
Bumetanide is a loop diuretic with good absorption and pharmacodynamic properties.{23240,23239} It acts as an inhibitor of the Na-K-Cl cotransporter 1 (NKCC1) and the kidney-specific NKCC2 (Ki = 0.5 and 59 μM for human and rabbit NKCC1, respectively).{23243,23244} Bumetanide also inhibits several isoforms of carbonic anhydrase.{23242}
Brand:CaymanSKU:- Bumetanide is a loop diuretic with good absorption and pharmacodynamic properties.{23240,23239} It acts as an inhibitor of the Na-K-Cl cotransporter 1 (NKCC1) and the kidney-specific NKCC2 (Ki = 0.5 and 59 μM for human and rabbit NKCC1, respectively).{23243,23244} Bumetanide also inhibits several isoforms of carbonic anhydrase.{23242}
Brand:CaymanSKU:- Bumetanide is a loop diuretic with good absorption and pharmacodynamic properties.{23240,23239} It acts as an inhibitor of the Na-K-Cl cotransporter 1 (NKCC1) and the kidney-specific NKCC2 (Ki = 0.5 and 59 μM for human and rabbit NKCC1, respectively).{23243,23244} Bumetanide also inhibits several isoforms of carbonic anhydrase.{23242}
Brand:CaymanSKU:- Bumetanide is a loop diuretic with good absorption and pharmacodynamic properties.{23240,23239} It acts as an inhibitor of the Na-K-Cl cotransporter 1 (NKCC1) and the kidney-specific NKCC2 (Ki = 0.5 and 59 μM for human and rabbit NKCC1, respectively).{23243,23244} Bumetanide also inhibits several isoforms of carbonic anhydrase.{23242}
Brand:CaymanSKU:-
Bumetanide-d5 is intended for use as an internal standard for the quantification of bumetanide (Item No. 14630) by GC- or LC-MS. Bumetanide is a loop diuretic with good absorption and pharmacodynamic properties.{23240,23239} It acts as an inhibitor of the Na-K-Cl cotransporter 1 (NKCC1) and the kidney-specific NKCC2 (Kis = 0.5 and 59 μM for human and rabbit NKCC1, respectively).{23243,23244} Bumetanide also inhibits several isoforms of carbonic anhydrase.{23242}
Brand:CaymanSKU:26773 - 1 mgAvailable on backorder
Bumetanide-d5 is intended for use as an internal standard for the quantification of bumetanide (Item No. 14630) by GC- or LC-MS. Bumetanide is a loop diuretic with good absorption and pharmacodynamic properties.{23240,23239} It acts as an inhibitor of the Na-K-Cl cotransporter 1 (NKCC1) and the kidney-specific NKCC2 (Kis = 0.5 and 59 μM for human and rabbit NKCC1, respectively).{23243,23244} Bumetanide also inhibits several isoforms of carbonic anhydrase.{23242}
Brand:CaymanSKU:26773 - 500 µgAvailable on backorder
Buparvaquone is a hydroxynaphthoquinone that inhibits electron transport by blocking cytochrome bc1 in parasites that cause leishmaniasis.{33636} Formulations containing buparvaquone are used to treat theileriosis, an infection by the parasites T. annulata and T. parva (in vitro EC50s of 1.5 x 10-8 M and 6.1 x 10-10 M, respectively).{33638,33637}
Brand:CaymanSKU:21704 -Out of stock
Buparvaquone is a hydroxynaphthoquinone that inhibits electron transport by blocking cytochrome bc1 in parasites that cause leishmaniasis.{33636} Formulations containing buparvaquone are used to treat theileriosis, an infection by the parasites T. annulata and T. parva (in vitro EC50s of 1.5 x 10-8 M and 6.1 x 10-10 M, respectively).{33638,33637}
Brand:CaymanSKU:21704 -Out of stock
Buparvaquone is a hydroxynaphthoquinone that inhibits electron transport by blocking cytochrome bc1 in parasites that cause leishmaniasis.{33636} Formulations containing buparvaquone are used to treat theileriosis, an infection by the parasites T. annulata and T. parva (in vitro EC50s of 1.5 x 10-8 M and 6.1 x 10-10 M, respectively).{33638,33637}
Brand:CaymanSKU:21704 -Out of stock
Buparvaquone is a hydroxynaphthoquinone that inhibits electron transport by blocking cytochrome bc1 in parasites that cause leishmaniasis.{33636} Formulations containing buparvaquone are used to treat theileriosis, an infection by the parasites T. annulata and T. parva (in vitro EC50s of 1.5 x 10-8 M and 6.1 x 10-10 M, respectively).{33638,33637}
Brand:CaymanSKU:21704 -Out of stock
Buphedrone is a substituted cathinone characterized by an ethyl group at the α position and an N-terminal methyl group. This metabolite of buphedrone features conversion of the β-keto group to β-hydroxy and is an enantiomeric mixture of the R,S and S,R orientations at carbons one and two, as in ephedrine. The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research purposes.
Brand:CaymanSKU:9001432 - 1 mgAvailable on backorder
Buphedrone is a substituted cathinone characterized by an ethyl group at the α position and an N-terminal methyl group. This metabolite of buphedrone features conversion of the β-keto group to β-hydroxy and is an enantiomeric mixture of the R,S and S,R orientations at carbons one and two, as in ephedrine. The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research purposes.
Brand:CaymanSKU:9001432 - 5 mgAvailable on backorder
Buphedrone is a substituted cathinone characterized by an ethyl group at the α position and an N-terminal methyl group. This metabolite of buphedrone features conversion of the β-keto group to β-hydroxy and is an enantiomeric mixture of the R,S and S,R orientations at carbons one and two, as in ephedrine. The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research purposes.
Brand:CaymanSKU:9001432 - 500 µgAvailable on backorder
Buphedrone is a substituted cathinone characterized by an ethyl group at the α position and an N-terminal methyl group. This metabolite of buphedrone features conversion of the β-keto group to β-hydroxy and is an enantiomeric mixture of the R,R and S,S orientations at carbons one and two, as in pseudoephedrine. The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research purposes.
Brand:CaymanSKU:9001438 - 1 mgAvailable on backorder
Buphedrone is a substituted cathinone characterized by an ethyl group at the α position and an N-terminal methyl group. This metabolite of buphedrone features conversion of the β-keto group to β-hydroxy and is an enantiomeric mixture of the R,R and S,S orientations at carbons one and two, as in pseudoephedrine. The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research purposes.
Brand:CaymanSKU:9001438 - 5 mgAvailable on backorder
Buphedrone is a substituted cathinone characterized by an ethyl group at the α position and an N-terminal methyl group. This metabolite of buphedrone features conversion of the β-keto group to β-hydroxy and is an enantiomeric mixture of the R,R and S,S orientations at carbons one and two, as in pseudoephedrine. The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research purposes.
Brand:CaymanSKU:9001438 - 500 µgAvailable on backorder
Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Out of stock
Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Out of stock
Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Out of stock
Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Out of stock
Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine (Item No. 16618) by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Available on backorder
Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine (Item No. 16618) by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Available on backorder
Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine (Item No. 16618) by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
Brand:CaymanSKU:-Available on backorder
Buprofezin is an insecticide that acts by inhibiting chitin synthesis.{39785} It inhibits chitin synthesis by 35% in N. lugens nymphs when used at a concentration of 10 ppm. Buprofezin (500 ppm) decreases the lifespan of adult T. vaporariorum with 17.9% mortality after 24 hours.{39786} It inhibits mitochondrial respiration when used at concentrations of 10 and 30 µM, reduces the expression of enzymes involved in the tricarboxylic acid (TCA) cycle, and stimulates glycolysis in HepG2 cells.{39787} It also dose-dependently increases the production of reactive oxygen species (ROS) in vitro. Buprofezin accumulates in mouse liver following oral administration of doses ranging from 46.3 to 417 mg/kg. It is not mutagenic and has LD50 values of 6,810 and 5,010 mg/kg in male and female rats, respectively.{39800} Formulations containing buprofezin have been used as insecticides.
Brand:CaymanSKU:24137 - 100 mgAvailable on backorder
Buprofezin is an insecticide that acts by inhibiting chitin synthesis.{39785} It inhibits chitin synthesis by 35% in N. lugens nymphs when used at a concentration of 10 ppm. Buprofezin (500 ppm) decreases the lifespan of adult T. vaporariorum with 17.9% mortality after 24 hours.{39786} It inhibits mitochondrial respiration when used at concentrations of 10 and 30 µM, reduces the expression of enzymes involved in the tricarboxylic acid (TCA) cycle, and stimulates glycolysis in HepG2 cells.{39787} It also dose-dependently increases the production of reactive oxygen species (ROS) in vitro. Buprofezin accumulates in mouse liver following oral administration of doses ranging from 46.3 to 417 mg/kg. It is not mutagenic and has LD50 values of 6,810 and 5,010 mg/kg in male and female rats, respectively.{39800} Formulations containing buprofezin have been used as insecticides.
Brand:CaymanSKU:24137 - 50 mgAvailable on backorder
Buspirone (hydrochloride) (Item No. 22028) is an analytical reference standard that is categorized as an anxiolytic.{34376} It modulates serotonin and dopamine receptors, undergoes rapid first-pass metabolism, and is metabolized to phenylpiperazine (Item No. 11203), which has high affinity for α-adrenergic receptors.{25892} This product is intended for research and forensic applications.
Brand:CaymanSKU:22028 -Out of stock
Buspirone (hydrochloride) (Item No. 22028) is an analytical reference standard that is categorized as an anxiolytic.{34376} It modulates serotonin and dopamine receptors, undergoes rapid first-pass metabolism, and is metabolized to phenylpiperazine (Item No. 11203), which has high affinity for α-adrenergic receptors.{25892} This product is intended for research and forensic applications.
Brand:CaymanSKU:22028 -Out of stock
Busulfan is an alkyl sulfonate that acts as an alkylating antineoplastic agent.{23714} It forms both intra- and interstrand crosslinks on DNA.{23711,23712} In mammals, busulfan causes profound and prolonged reduction in the generation of hematopoietic progenitors without significantly affecting lymphocyte levels or humoral antibody responses.{23713}
Brand:CaymanSKU:- Busulfan is an alkyl sulfonate that acts as an alkylating antineoplastic agent.{23714} It forms both intra- and interstrand crosslinks on DNA.{23711,23712} In mammals, busulfan causes profound and prolonged reduction in the generation of hematopoietic progenitors without significantly affecting lymphocyte levels or humoral antibody responses.{23713}
Brand:CaymanSKU:- Busulfan is an alkyl sulfonate that acts as an alkylating antineoplastic agent.{23714} It forms both intra- and interstrand crosslinks on DNA.{23711,23712} In mammals, busulfan causes profound and prolonged reduction in the generation of hematopoietic progenitors without significantly affecting lymphocyte levels or humoral antibody responses.{23713}
Brand:CaymanSKU:- Busulfan is an alkyl sulfonate that acts as an alkylating antineoplastic agent.{23714} It forms both intra- and interstrand crosslinks on DNA.{23711,23712} In mammals, busulfan causes profound and prolonged reduction in the generation of hematopoietic progenitors without significantly affecting lymphocyte levels or humoral antibody responses.{23713}
Brand:CaymanSKU:-